Acotec Scientific Holdings Ltd. has announced that it has received registration approval from the PRC National Medical Products Administration for its Sirolimus-Coated Coronary Balloon Dilatation Catheter, AcoArt Canna®. This approval marks a significant milestone for the company, allowing it to proceed with marketing activities in the PRC market when deemed appropriate. The AcoArt Canna® is designed for the dilatation treatment of de novo coronary artery bifurcation lesions with vessel diameters ranging from 2.0mm to 4.0mm. Clinical trials have demonstrated its efficacy and safety, with no statistically significant difference in diameter stenosis compared to the control group using paclitaxel-coated catheters. However, the company cautions that it may not ultimately be able to market the product.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。